comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Free Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1

GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies

28.76

★★★★☆4.8 (126)

Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis - Jorge - 2026 - Arthritis & Rheumatology

28.36

★★★★★4.9 (98)

PDF) Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis

26.51

★★★★★5.0 (157)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

29.63

★★★★★4.7 (84)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome

20.72

★★★★★4.9 (203)

It's important to study the difference in GLP-1 medications. Our analysis found tirzepatide is associated with a lower risk of serious heart and kidney complications compared to dulaglutide in adults with Type

21.34

★★★★★5.0 (176)

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

29.81

★★★★★4.8 (132)